항생제 제휴 및 라이선싱 계약(2016-2026년)

The definitive benchmark for antibiotic dealmaking

Antibiotic partnering is shaped by the growing challenge of antimicrobial resistance, with deal structures reflecting the unique scientific, regulatory, and commercial dynamics of developing anti-infective therapies.

This report provides a comprehensive and structured analysis of 140+ antibiotic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how antibiotic deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by development stage, mechanism of action, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a scientifically critical and economically distinct therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within antibiotic partnerships, particularly in areas influenced by public health priorities and non-traditional commercial models.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark anti-infective transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 140+ antibiotic collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, mechanism, and development stage)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for antibiotic dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how antibiotic partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibiotic dealmaking

• 2.1. Introduction
• 2.2. Antibiotic deals over the years
• 2.3. Most active antibiotic dealmakers
• 2.4. Antibiotic deals by deal type
• 2.5. Antibiotic deals by therapy area
• 2.6. Antibiotic deals by industry sector
• 2.7. Deal terms for antibiotic deals
  • 2.7.1 Antibiotic deals headline values
  • 2.7.2 Antibiotic deal upfront payments
  • 2.7.3 Antibiotic deal milestone payments
  • 2.7.4 Antibiotic royalty rates

Chapter 3 - Leading antibiotic deals

• 3.1. Introduction
• 3.2. Top antibiotic deals by value

Chapter 4 - Most active antibiotic dealmakers

• 4.1. Introduction
• 4.2. Most active antibiotic dealmakers
• 4.3. Most active antibiotic deals company profiles

Chapter 5 - Antibiotic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Antibiotic contracts dealmaking directory

Chapter 6 - Antibiotic dealmaking by technology type

• Deal directory
• Deal directory - Antibiotic deals by company A-Z
• Deal directory - Antibiotic deals by deal type
• Deal directory - Antibiotic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Antibiotic deals since 2016
• Figure 2: Active antibiotic dealmaking activity since 2016
• Figure 3: Antibiotic deals by deal type since 2016
• Figure 4: Antibiotic deals by therapy area since 2016
• Figure 5: Antibiotic deals by industry sector since 2016
• Figure 6: Antibiotic deals with a headline value
• Figure 7: Antibiotic deals with an upfront value
• Figure 8: Antibiotic deals with a milestone value
• Figure 9: Antibiotic deals with a royalty rate value
• Figure 10: Top antibiotic deals by value since 2016
• Figure 11: Most active antibiotic dealmakers since 2016
• Figure 12: Antibiotic deals by technology type since 2016